

MT2022-60: A phase II study of Pembrolizumab+ BEAM conditioning regimen before autologous stem cell transplant (ASCT) followed by pembrolizumab maintenance in patients of relapsed classic Hodgkin lymphoma

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- eligible for autologous stem cell transplant (ASCT) with BEAM conditioning regimen - unable to do strenuous activities but can walk and perform light or sedentary tasks, such as housework or office work - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- known active central nervous system (CNS) disease - history of or active autoimmune disease, or other syndrome that requires systemic steroids or autoimmune agents - had an allogenic tissue/solid organ transplant - women who are pregnant or breast feeding

Conditions & Interventions

Interventions:

Procedure: Autologous stem cell transplant, Drug: Carmustine, Drug: Cytarabine, Drug: Etoposide, Drug: Melphalan, Drug: Pembrolizumab

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma

More Information

Description: This drug study aims to estimate at initiation of treatment to the occurrence of disease progression or expiration at 1 years post autologous stem cell transplant of classical Hodgkin's lymphoma patients treated with BEAM autologous stem cell transplant combined with pembrolizumab given pretransplant and for 1 year post-transplant maintenance.

Study Contact: Caitlynn Olson - olso9051@umn.edu

Principal Investigator: Sanjal Desai

Phase: PHASE2

IRB

Number: STUDY00020893

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.